# US 2021/0275607 A1 · Compositions comprising bacterial strains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275607 A1
- Document ID: US20210275607A1
- Status: Published application
- Kind: A1
- Application number: 17/149,990
- Filed: 2021-01-15
- Published: 2021-09-09
- Earliest claimed: 2018-07-16
- Assignees: 4D Pharma Research Limited
- Applicants: 4D Pharma Research Limited
- Inventors: Imke MULDER; Alexander STEVENSON; Helene SAVIGNAC
- Web page: https://patentgrep.com/patent/US20210275607A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compositions comprising bacterial strains for treating and preventing lung injury or lung disease.

## Claims

### Claim at position 1

-17. (canceled)

### Claim 18

A method of treating lung injury or lung disease in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a bacterial strain of the genus Blautia, wherein the bacterial strain comprises a polynucleotide sequence of a 16S rRNA gene that has at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO:1, and a pharmaceutically acceptable excipient, diluent, or carrier,
wherein the lung injury or the lung disease is non-asthma lung injury or non-asthma lung disease.

### Claim 19 (depends on 18)

The method of claim 18, wherein the lung injury or the lung disease is mediated by inflammation in a lung tissue of the subject.

### Claim 20 (depends on 19)

The method of claim 19, wherein the pharmaceutical composition reduces inflammation in the lung tissue.

### Claim 21 (depends on 19)

The method of claim 19, wherein the lung injury or the lung disease comprises bronchiectasis, bronchiolitis, bronchitis, chronic cough, cystic fibrosis, emphysema, human metapneumovirus (hMPV) infection, influenza, pandemic flu, pertussis, pleurisy, pleural cavity diseases, pneumonia, respiratory syncytial virus (RSV), sarcoidosis, severe acute respiratory syndrome (SARS), tuberculosis, or upper respiratory tract infections.

### Claim 22 (depends on 18)

The method of claim 18, wherein the lung injury or the lung disease comprises acute respiratory distress syndrome (ARDS) or chronic obstructive pulmonary disease (COPD).

### Claim 23 (depends on 18)

The method of claim 18, wherein the pharmaceutical composition reduces one or more of neutrophil inflammation, haemorrhage, oedema, necrosis, and atelectasis in the lung tissue.

### Claim 24 (depends on 23)

The method of claim 23, wherein the pharmaceutical composition reduces all of neutrophil inflammation, haemorrhage, oedema, necrosis, and atelectasis in the lung tissue.

### Claim 25 (depends on 18)

The method of claim 18, wherein the bacterial strain has a 16s rRNA gene sequence that has at least 98% sequence identity to the polynucleotide sequence of SEQ ID NO:1, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2.

### Claim 26 (depends on 18)

The method of claim 18, wherein the bacterial strain has a 16s rRNA gene sequence comprising the polynucleotide sequence of SEQ ID NO:1.

### Claim 27 (depends on 18)

The method of claim 18, wherein the pharmaceutical composition comprises a single strain of the genus Blautia.

### Claim 28 (depends on 18)

The method of claim 18, wherein the pharmaceutical composition comprises the bacterial strain of the genus Blautia as a part of a microbial consortium.

### Claim 29 (depends on 18)

The method of claim 18, wherein the bacterial strain is of the species Blautia hydrogenotrophica.

### Claim 30 (depends on 29)

The method of claim 29, wherein the bacterial strain is the strain deposited as accession number DSM 14294 at the Deutsche Sammlung von Mikroorganismen (German Microorganism Collection), a biotype thereof, or a derivative thereof.

### Claim 31 (depends on 18)

The method of claim 18, wherein the pharmaceutical composition is formulated for oral delivery.

### Claim 32 (depends on 18)

The method of claim 18, wherein the bacterial strain is lyophilized.

### Claim 33 (depends on 18)

The method of claim 18, wherein the bacterial strain is viable.

### Claim 34 (depends on 18)

The method of claim 18, wherein the bacterial strain is capable of colonizing the intestine.

### Claim 35 (depends on 18)

The method of claim 18, wherein the 95% sequence identity is determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2.

### Claim 36

A method of reducing damage in a lung tissue caused by lung injury or lung disease in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a bacterial strain of the genus Blautia, wherein the bacterial strain comprises a polynucleotide sequence of a 16S rRNA gene that has at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO:1, and a pharmaceutically acceptable excipient, diluent, or carrier,
wherein the lung injury or the lung disease is non-asthma lung injury or non-asthma lung disease.

### Claim 37 (depends on 35)

The method of claim 35, wherein the lung injury or the lung disease comprises acute respiratory distress syndrome (ARDS) or chronic obstructive pulmonary disease (COPD).
